Racial differences in prostate tumor microenvironment: implications for disparate clinical outcomes and potential opportunities.
Prostate cancer
racial disparity
tumor microenvironment
Journal
Cancer health disparities
ISSN: 2573-9530
Titre abrégé: Cancer Health Disparities
Pays: United States
ID NLM: 101728460
Informations de publication
Date de publication:
2022
2022
Historique:
entrez:
13
2
2023
pubmed:
14
2
2023
medline:
14
2
2023
Statut:
ppublish
Résumé
Disparities in cancer incidence and outcome are common among the racial and ethnical minorities in the United States and are of significant social and clinical concern. Prostate cancer is the most commonly diagnosed non-cutaneous malignancy in American men and exhibits substantial racial disparities with African American men bearing the highest burden in terms of incidence and mortality. A multitude of factors, including socioeconomic, behavioral, and access to healthcare, have been implicated as the underlying causes of such disparities. More recent data also suggest that there are inherent molecular and biological differences in prostate tumors of patients having distinct racial backgrounds. Tumor microenvironment has tremendous impact on the course of cancer progression and clinical outcome and may also contribute to the racial disparities observed in prostate cancer. Therefore, a better understanding of critical differences in the tumor microenvironment components may provide newer directions to study the biological causes of prostate cancer health disparities and may identify novel therapeutic targets. This review discusses the findings related to the tumor microenvironment differences between African American and Caucasian American prostate cancer patients and makes suggestion regarding their potential significance in prostate cancer disparities.
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : NCI NIH HHS
ID : R01 CA204801
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA231925
Pays : United States
Déclaration de conflit d'intérêts
Conflicts of interest The authors declare that they have no conflicts of interest with the contents of this article.
Références
Cancers (Basel). 2020 Aug 23;12(9):
pubmed: 32842503
Urol Clin North Am. 2016 Aug;43(3):279-88
pubmed: 27476121
J Mol Med (Berl). 2012 Nov;90(11):1343-55
pubmed: 22660275
Int J Mol Sci. 2019 May 31;20(11):
pubmed: 31151317
CA Cancer J Clin. 2021 Jul;71(4):359
pubmed: 34232515
Nat Med. 2003 Jun;9(6):669-76
pubmed: 12778165
Cancer Res. 2009 May 1;69(9):3727-30
pubmed: 19383906
Nature. 2000 Sep 14;407(6801):249-57
pubmed: 11001068
Semin Oncol. 2014 Apr;41(2):267-80
pubmed: 24787298
Int J Cancer. 2020 Mar 15;146(6):1686-1699
pubmed: 31381135
J Neuroimmune Pharmacol. 2013 Mar;8(1):7-14
pubmed: 22886869
Int J Mol Sci. 2022 Mar 11;23(6):
pubmed: 35328458
Tumori. 2016 Jan-Feb;102(1):65-70
pubmed: 26429642
Oncogene. 2006 Oct 5;25(45):6113-22
pubmed: 16652143
Prostate. 2020 Jan;80(1):3-16
pubmed: 31702061
Clin Cancer Res. 2021 Jan 1;27(1):320-329
pubmed: 33037017
Cancers (Basel). 2020 Sep 22;12(9):
pubmed: 32971847
Nat Commun. 2021 Feb 10;12(1):935
pubmed: 33568675
Commun Biol. 2021 Jun 3;4(1):670
pubmed: 34083737
Prostate. 2022 Jun;82(8):883-893
pubmed: 35254710
Cancer Res. 2008 Feb 1;68(3):927-36
pubmed: 18245496
Onco Targets Ther. 2021 Feb 25;14:1417-1427
pubmed: 33664576
Biochem Biophys Res Commun. 2017 May 6;486(3):607-612
pubmed: 28341124
Front Immunol. 2021 Apr 23;12:664845
pubmed: 33968066
Semin Cell Dev Biol. 2010 Feb;21(1):26-32
pubmed: 19948237
Cancer Epidemiol Biomarkers Prev. 2021 Mar;30(3):539-544
pubmed: 33293340
Oncotarget. 2021 Jul 20;12(15):1457-1469
pubmed: 34316327
Prostate Cancer Prostatic Dis. 2020 Sep;23(3):517-526
pubmed: 32111923
Cancer Res. 2016 Apr 1;76(7):1860-8
pubmed: 26921337
Front Oncol. 2021 Nov 08;11:770500
pubmed: 34820334
Cancers (Basel). 2021 May 28;13(11):
pubmed: 34071280
Cancer Rep (Hoboken). 2021 Oct;4(5):e1340
pubmed: 33599076
Oncol Lett. 2014 Oct;8(4):1409-1421
pubmed: 25202343
PLoS Genet. 2020 Feb 14;16(2):e1008641
pubmed: 32059012
Infect Agent Cancer. 2009 Feb 10;4 Suppl 1:S3
pubmed: 19208208
Int J Cancer. 2014 Jan 1;134(1):81-91
pubmed: 23754304
J Natl Cancer Inst. 1990 Jan 3;82(1):4-6
pubmed: 1688381
J Immunol. 2006 Nov 15;177(10):7398-405
pubmed: 17082659
Clin Cancer Res. 2003 Oct 15;9(13):4792-801
pubmed: 14581350
Cancer Lett. 2016 Sep 28;380(1):340-8
pubmed: 26828013
J Pathol. 2013 Sep;231(1):77-87
pubmed: 23729330
Mod Pathol. 2018 Oct;31(10):1539-1552
pubmed: 29849114
Clin Prostate Cancer. 2003 Dec;2(3):153-9
pubmed: 15040858
Front Immunol. 2019 Mar 28;10:603
pubmed: 30984182
J Immunother Cancer. 2018 Jun 20;6(1):61
pubmed: 29921320
Mol Cancer. 2019 Mar 30;18(1):70
pubmed: 30927908
Int J Mol Sci. 2018 Apr 22;19(4):
pubmed: 29690565
Cancer Res. 2018 Nov 1;78(21):6134-6145
pubmed: 30181178
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Am J Mens Health. 2018 Nov;12(6):1807-1823
pubmed: 30203706
BMC Cancer. 2021 Jul 22;21(1):846
pubmed: 34294073
Clin Cancer Res. 2004 Dec 15;10(24):8728-34
pubmed: 15623658
MMWR Morb Mortal Wkly Rep. 2020 Oct 16;69(41):1473-1480
pubmed: 33056955
Prostate. 2002 Mar 1;50(4):216-21
pubmed: 11870799
Mol Med Rep. 2018 Aug;18(2):1305-1310
pubmed: 29901197
Prostate. 2018 May;78(7):479-490
pubmed: 29542173
Clin Cancer Res. 2018 Sep 15;24(18):4612-4626
pubmed: 29691294
Clin Prostate Cancer. 2004 Dec;3(3):165-73
pubmed: 15636683
Br J Radiol. 2017 May;90(1073):20160693
pubmed: 28256901
Cancer Immunol Res. 2019 Apr;7(4):559-571
pubmed: 30894377
J Clin Invest. 2019 Mar 25;129(5):1845-1862
pubmed: 30907747
J Clin Pathol. 2021 Sep;74(9):548-552
pubmed: 34039664
Sci Rep. 2016 Aug 01;6:30691
pubmed: 27476486
Cancer. 2017 Jun 15;123(12):2312-2319
pubmed: 28436011
Front Oncol. 2015 Jul 08;5:128
pubmed: 26217583
Am J Clin Exp Urol. 2017 Nov 09;5(3):34-48
pubmed: 29181436
Cancers (Basel). 2019 Nov 25;11(12):
pubmed: 31769418
J Clin Oncol. 2002 Nov 1;20(21):4368-80
pubmed: 12409337
Front Biosci (Landmark Ed). 2017 Jan 1;22(5):772-782
pubmed: 27814645
Urology. 2003 Dec 22;62(6 Suppl 1):3-12
pubmed: 14706503
Cancer Epidemiol Biomarkers Prev. 2017 Jun;26(6):845-853
pubmed: 28292923
Cancer Immunol Immunother. 2008 Jan;57(1):43-52
pubmed: 17579857
J Urol. 2003 Sep;170(3):990-3
pubmed: 12913756
Front Mol Biosci. 2021 Apr 29;8:667067
pubmed: 33996912
J Carcinog. 2011;10:20
pubmed: 21886458
Oncotarget. 2016 Jul 18;8(42):71393-71399
pubmed: 29069714
Am J Cancer Res. 2021 Apr 15;11(4):1012-1030
pubmed: 33948343
J Clin Oncol. 2004 Jul 15;22(14):2927-41
pubmed: 15184404
Cancer Immunol Res. 2015 Sep;3(9):1008-16
pubmed: 25968455
Int J Cancer. 2017 Aug 15;141(4):731-743
pubmed: 28510291
Semin Cell Dev Biol. 2010 Feb;21(1):33-9
pubmed: 19896548
Oncotarget. 2017 May 16;8(32):53763-53779
pubmed: 28881849
Mol Cancer Res. 2020 Jan;18(1):153-165
pubmed: 31604846
Cancers (Basel). 2020 Jul 13;12(7):
pubmed: 32668821